148 related articles for article (PubMed ID: 22524657)
21. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
[TBL] [Abstract][Full Text] [Related]
22. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.
Lin X; Wang X; Capek HL; Simone LC; Tuli A; Morris CR; Reber AJ; Solheim JC
Cancer Immunol Immunother; 2009 May; 58(5):729-36. PubMed ID: 18828016
[TBL] [Abstract][Full Text] [Related]
23. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients.
Zia A; Schildberg FW; Funke I
Int J Cancer; 2001 Aug; 93(4):566-70. PubMed ID: 11477561
[TBL] [Abstract][Full Text] [Related]
24. Loss of HLA heavy chain and beta 2-microglobulin in HLA negative tumours.
Cabrera T; Concha A; Ruiz-Cabello F; Garrido F
Scand J Immunol; 1991 Aug; 34(2):147-52. PubMed ID: 1866599
[TBL] [Abstract][Full Text] [Related]
25. Mild acid treatment induces cross-reactivity of 4H84 monoclonal antibody specific to nonclassical HLA-G antigen with classical HLA class I molecules.
Poláková K; Bennink JR; Yewdell JW; Bystrická M; Bandzuchová E; Russ G
Hum Immunol; 2003 Feb; 64(2):256-64. PubMed ID: 12559628
[TBL] [Abstract][Full Text] [Related]
26. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S
Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289
[TBL] [Abstract][Full Text] [Related]
27. High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines.
Hiraki A; Fujii N; Murakami T; Kiura K; Aoe K; Yamane H; Masuda K; Maeda T; Sugi K; Darzynkiewicz Z; Tanimoto M; Harada M
Anticancer Res; 2004; 24(3a):1525-8. PubMed ID: 15274319
[TBL] [Abstract][Full Text] [Related]
28. Human leukocyte class I antigen and beta2-microglobulin expression in conjunctival dysplasia, carcinoma in situ, and squamous cell carcinoma.
Krishnakumar S; Lakshmi SA; Pusphparaj V; Iyer A; Abhyankar D; Biswas J
Cornea; 2005 Apr; 24(3):337-41. PubMed ID: 15778609
[TBL] [Abstract][Full Text] [Related]
29. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.
Wang X; Campoli M; Cho HS; Ogino T; Bandoh N; Shen J; Hur SY; Kageshita T; Ferrone S
J Immunol Methods; 2005 Apr; 299(1-2):139-51. PubMed ID: 15896802
[TBL] [Abstract][Full Text] [Related]
30. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules.
Menier C; Saez B; Horejsi V; Martinozzi S; Krawice-Radanne I; Bruel S; Le Danff C; Reboul M; Hilgert I; Rabreau M; Larrad ML; Pla M; Carosella ED; Rouas-Freiss N
Hum Immunol; 2003 Mar; 64(3):315-26. PubMed ID: 12590976
[TBL] [Abstract][Full Text] [Related]
31. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
32. Clinical implication of HLA class I expression in breast cancer.
Kaneko K; Ishigami S; Kijima Y; Funasako Y; Hirata M; Okumura H; Shinchi H; Koriyama C; Ueno S; Yoshinaka H; Natsugoe S
BMC Cancer; 2011 Oct; 11():454. PubMed ID: 22014037
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity at 6p21 underlying [corrected] HLA class I downregulation in Chinese primary esophageal squamous cell carcinomas.
Yang Y; Zhang J; Miao F; Wei J; Shen C; Shen Y; Xie W
Tissue Antigens; 2008 Aug; 72(2):105-14. PubMed ID: 18721270
[TBL] [Abstract][Full Text] [Related]
34. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.
Vitale M; Rezzani R; Rodella L; Zauli G; Grigolato P; Cadei M; Hicklin DJ; Ferrone S
Cancer Res; 1998 Feb; 58(4):737-42. PubMed ID: 9485029
[TBL] [Abstract][Full Text] [Related]
35. Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer.
McEvoy CR; Seshadri R; Morley AA; Firgaira FA
Tissue Antigens; 2002 Sep; 60(3):235-43. PubMed ID: 12445306
[TBL] [Abstract][Full Text] [Related]
36. HLA class I molecules expression: evaluation of different immunocytochemical methods in malignant lesions.
Facoetti A; Capelli E; Nano R
Anticancer Res; 2001; 21(4A):2435-40. PubMed ID: 11724304
[TBL] [Abstract][Full Text] [Related]
37. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.
Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570
[TBL] [Abstract][Full Text] [Related]
38. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.
Baba T; Hanagiri T; Ichiki Y; Kuroda K; Shigematsu Y; Mizukami M; Sugaya M; Takenoyama M; Sugio K; Yasumoto K
Cancer Sci; 2007 Nov; 98(11):1795-802. PubMed ID: 17725806
[TBL] [Abstract][Full Text] [Related]
39. Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.
Saio M; Teicher M; Campbell G; Feiner H; Delgado Y; Frey AB
Clin Exp Metastasis; 2004; 21(3):243-9. PubMed ID: 15387374
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of HLA class I antigens in breast cancer: association with prognosis.
Gudmundsdóttir I; Gunnlaugur Jónasson J; Sigurdsson H; Olafsdóttir K; Tryggvadóttir L; Ogmundsdóttir HM
Int J Cancer; 2000 Nov; 89(6):500-5. PubMed ID: 11102894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
